Table 1 Clinical and biochemical characteristics of the study subjects with or without NAFLD.

From: Association between the cardiometabolic index and NAFLD and fibrosis

 

Non-NAFLD

NAFLD

 
 

Total

CAP < 274 dB/m (n = 1685)

CAP ≥ 274 dB/m (n = 1311)

P

CMI [M (P25, P75)]

0.46 (0.25,0.81)

0.32 (0.20,0.54)

0.71 (0.43,1.11)

< 0.001#

CMI quartile

  Q1 (≤ 0.25)

749 (25.00)

634 (37.63)

115 (8.77)

< 0.001

  Q2 (0.25 ~ 0.46)

749 (25.00)

504 (29.91)

245 (18.69)

  Q3 (0.46 ~ 0.81)

749 (25.00)

340 (20.18)

409 (31.20)

  Q4 (> 0.81)

749 (25.00)

207 (12.28)

542 (41.34)

Sex

  Men

1355 (45.23)

711 (42.20)

644 (49.12)

< 0.001

  Women

1641 (54.77)

974 (57.80)

667 (50.88)

Age [M (P25, P75)]

51.0 (35.0,64.0)

46.0 (32.0,62.0)

54.0 (41.0,65.0)

< 0.001#

BMI [M (P25, P75)]

28.6 (24.7,33.5)

26.0 (23.0,29.9)

32.0 (28.2,37.1)

< 0.001#

Race

  Mexican American

391 (13.05)

166 (9.85)

225 (17.16)

< 0.001

  Other Hispanic

310 (10.35)

173 (10.27)

137 (10.45)

  Non-Hispanic white

993 (33.14)

534 (31.69)

459 (35.01)

  Non-Hispanic black

739 (24.67)

474 (28.13)

265 (20.21)

  Other race—Including multi-racial

563 (18.79)

338 (20.06)

225 (17.16)

Smoke

  Yes

1121 (37.44)

599 (35.59)

522 (39.82)

< 0.001

  No

1873 (62.56)

1084 (64.41)

789 (60.18)

Diabetes

  Yes

448 (14.96)

150 (8.91)

298 (22.73)

< 0.001

  No

2546 (85.04)

1533 (91.09)

1013 (77.27)

Hypertension

  Yes

1099 (36.74)

475 (28.26)

624 (47.63)

< 0.001

  No

1892 (63.26)

1206 (71.74)

686 (52.37)

TG (mmol/L) [M (P25, P75)]

1.01 (0.68,1.50)

0.81 (0.60,1.21)

1.30 (0.90,1.84)

< 0.001#

TC (mmol/L) [M (P25, P75)]

4.68 (4.06,5.40)

4.63 (4.01,5.33)

4.76 (4.14,5.51)

< 0.001#

HDL-C (mmol/L) [M (P25, P75)]

1.32 (1.09,1.60)

1.42 (1.19,1.71)

1.19 (1.03,1.45)

< 0.001#

LDL-C (mmol/L) [M (P25, P75)]

2.77 (2.20,3.36)

2.69 (2.17,3.31)

2.85 (2.25,3.44)

< 0.001#

AST(IU/L) [M (P25, P75)]

19.0 (15.0,23.0)

18.0 (15.0,22.0)

19.0 (16.0,25.0)

< 0.001#

ALT(IU/L) [M (P25, P75)]

17.0 (13.0,25.0)

15.0 (11.0,21.0)

21.0 (15.0,30.0)

< 0.001#

GGT(IU/L) [M (P25, P75)]

21.0 (15.0,30.0)

18.0 (13.0,25.0)

24.0 (18.0,37.0)

< 0.001#

ALB(g/L) [M (P25, P75)]

40.0 (38.0,42.0)

41.0 (39.0,43.0)

40.0 (38.0,42.0)

< 0.001#

BUN (mmol/L) [M (P25, P75)]

5.0 (3.9,6.1)

4.6 (3.9,6.1)

5.0 (3.9,6.1)

< 0.001#

Cr(mmol/L) [M (P25, P75)]

73.4 (61.9,86.6)

73.4 (61.9,87.5)

74.4 (61.0,88.8)

< 0.001#

TB (umol/L) [M (P25, P75)]

6.8 (5.1,10.3)

6.8 (5.1,10.3)

7.1 (5.1,10.4)

< 0.001#

UA (umol/L) [M (P25, P75)]

315.2 (261.7, 374.7)

297.4 (249.8, 350.9)

339.0 (285.5, 398.5)

< 0.001#

  1. Values are n (%) or mean (standard deviation) or median (P25, P75).
  2. NAFLD, nonalcoholic fatty liver disease; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; ALT, alanine aminotransferase; ALB, albumin; GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; TB, total bilirubin; UA, uric acid; LSM, liver stiffness measurement; CMI, cardiometabolic index.
  3. "#" indicates that the rank-sum test was used.